Feature Video
Sponsored Content: Dr. Shannon Westin on PARP Inhibition for Ovarian Cancer
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
The Importance of Seeing an Ovarian Cancer Specialist
BY Renee Cowan

Renee Cowan, gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center (MSK), discusses the importance of patients with ovarian cancer seeing an oncologist who specializes in the field.
Too Few Women With Breast or Ovarian Cancer Undergo Genetic Testing
BY Brielle Urciuoli
Women with ovarian or breast cancer often don’t receive the genetic testing they need in order to devise the best treatment plans, a new study says.
What Ovarian Cancer Taught Me About Myself and Others
BY Kelly Irvin
Ovarian cancer is a hard taskmaster, but cancer teaches us important life, faith and family lessons
Nausea, Vomiting No Longer a Top Chemotherapy Concern Among Patients
BY Brielle Urciuoli
Nausea and vomiting are no longer top concerns for patients undergoing chemotherapy. Socio-psychological concerns, instead, have jumped to the forefront.
Putting Ovarian Self-Awareness in Action with Bright Pink
BY Bright Pink
September is Ovarian Cancer Awareness Month, but many people still aren’t aware of the symptoms and risk factors that can sometimes lead to an ovarian cancer diagnosis. Here are two steps you can take to personalize your approach to ovarian health management by being "ovarian self-aware."
Finding More Molecular Targets for Ovarian Cancer to Personalize Treatment
BY Angelica Welch
In a recent study, researchers were working on identifying different molecular targets to better provide personalized care to patients with ovarian cancer. To do this, they examined more than 4,000 tumor specimins.
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
BY Danielle Bucco
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
J&J Ordered to pay $417 Million in Ovarian Cancer Case
BY Brielle Urciuoli
Another case has been settled regarding Johnson & Johnson's Baby Powder and its possible link to ovarian cancer.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Ovarian CURE discussion group.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Ovarian Epithelial Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial cancer.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment.
Ovarian Germ Cell Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian germ cell tumors.
Ovarian Low Malignant Potential Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.
Prevention, Genetics, Causes
Information related to prevention, genetics, risk factors
Ovarian Cancer Prevention (PDQ®)
Expert-reviewed information summary about factors that may influence the risk of developing ovarian cancer and about research aimed at the prevention of this disease.
Screening and Testing
Information about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
Ovarian Cancer Screening (PDQ®)
Expert-reviewed information summary about tests used to detect or screen for ovarian cancer.
//For side ad protocol